12/02/2024
7:05 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/27/2024
3:44 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/14/2024
2:19 PM | JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/08/2024
4:34 PM | GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024
6:11 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2024
3:07 PM | Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
| Form SC 13G/A | |
09/25/2024
7:54 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
09/24/2024
6:41 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/24/2024
6:41 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/23/2024
4:27 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/23/2024
4:30 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/20/2024
5:12 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/20/2024
4:39 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/19/2024
4:50 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
6:55 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2024
8:00 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2024
7:56 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/28/2024
3:39 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024
7:15 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/22/2024
5:05 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024
4:21 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/09/2024
4:52 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/09/2024
4:16 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/07/2024
3:30 PM | Ligand Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/17/2024
4:10 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/10/2024
3:02 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/08/2024
6:38 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/02/2024
6:44 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
6:45 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
6:45 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
6:45 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
8:10 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2024
6:45 PM | Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:25 PM | Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:26 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:26 PM | Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:26 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:27 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:27 PM | Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
4:14 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/17/2024
6:59 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Lock in this disruptor’s share price before 12/5 (Ad) Spencer Rascoff co-founded Zillow. Austin Allison sold his company to Zillow for $125M. Now they’ve joined forces to launch a venture transforming the $1.3T vacation home market – and the results are already turning heads.
This company is leading the co-ownership revolution, offering buyers a chance to own a fraction of a luxury vacation home instead of the entire thing. It’s a model that’s unlocked new demand and earned them over $100M in gross profits in four years. Don’t miss your chance to maximize your stake in this co-ownership revolution. |
05/17/2024
7:00 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/17/2024
4:45 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
4:39 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024
6:34 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/15/2024
5:01 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024
1:45 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144/A | |
05/14/2024
6:42 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024
5:14 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024
4:32 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
5:03 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024
5:06 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024
3:11 PM | Ligand Pharmaceuticals (Filer)
| Form DEFA14A | |
05/07/2024
6:36 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/02/2024
5:07 PM | Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/26/2024
5:35 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/27/2024
4:47 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/07/2024
12:27 PM | Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2024
4:28 PM | Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/05/2024
5:12 PM | Ligand Pharmaceuticals (Subject)
Sabba Stephen L (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/29/2024
5:49 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
5:50 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
5:50 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
5:50 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
3:49 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144/A | |
02/29/2024
3:16 PM | Ligand Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/28/2024
5:05 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/28/2024
4:43 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/27/2024
6:24 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/16/2024
7:10 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
7:10 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
7:10 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
7:10 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
5:26 AM | Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
| Form SC 13G | |
02/13/2024
2:39 PM | JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/12/2024
6:42 PM | GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G | |
01/22/2024
1:03 PM | BlackRock Inc. (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
01/04/2024
3:07 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/04/2024
3:07 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
2:27 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
2:27 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
